FrancophonIA/ELRC3.0 huggingface dataset:
English: A population pharmacokinetic analysis evaluated avatrombopag plasma exposures in patients with mild to moderate hepatic impairment based on Model for End-Stage Liver Disease (MELD) scores and Child-Turcotte-Pugh scores.
Maltese: Analiżi farmakokinetika tal-popolazzjoni evalwat l-esponimenti għal avatrombopag fil-plażma f'pazjenti b'indeboliment tal-fwied ħafif sa moderat abbażi ta' punteġġi tal-Mudell għall-Mard tal-Fwied tal-Fażi tat-Tmiem (MELD, Model for End-Stage Liver Disease) u punteġġi ta' Child-Turcotte-Pugh.
English: Reproductive and Developmental Toxicity
Maltese: EFFETTIV TAL-PRODOTT MEDIĊINALI
English: In the low baseline platelet count cohort, the mean baseline platelet count for the avatrombopag-treated group was 32.7 x 109/L and for placebo-treated patients was 32.5 x 109/L.
Maltese: Fil-koort tal-għadd baxx tal-plejtlits fil-linja bażi, l-għadd medju tal-plejtlits fil-linja bażi għall-grupp ittrattat b'avatrombopag kien 32.7 x 109/L u għall-pazjenti ttrattati bi plaċebo kien 32.5 x 109/L.
English: In each study, patients were assigned to the low baseline platelet count cohort (˂ 40 x 109/L) or the high baseline platelet count cohort (≥ 40 to ˂ 50 x 109/L) based on their platelet count at baseline.
Maltese: F'kull studju, il-pazjenti ġew assenjati għall-koort tal-għadd baxx tal-plejtlits fil-linja bażi (˂ 40 x 109/L) jew fil-koort tal-għadd għoli tal-plejtlits fil-linja bażi (≥ 40 sa ˂ 50 x 109/L) abbażi tal-għadd tal-plejtlits tagħhom fil-linja bażi.
English: This medicine can pass into breast milk.
Maltese: - Din il-mediċina ġiet mogħtija lilek biss.
English: Retreatment
Maltese: Tul tat-trattament
English: It belongs to a group of medicines called thrombopoietin receptor agonists.
Maltese: L-UŻU Prodott mediċinali li jingħata bir-riċetta tat-tabib.
English: Duration of treatment Due to limited information, avatrombopag should not be taken for more than 5 days.
Maltese: Minħabba informazzjoni limitata, avatrombopag m'għandux jittieħed għal aktar minn 5 ijiem.
English: The European Medicines Agency has waived the obligation to submit the results of studies with Doptelet in all subsets of the paediatric population in thrombocytopenia secondary to liver disease (see section 4.2 for information on paediatric use).
Maltese: Billi tirrapporta l-effetti sekondarji tista' tgħin biex tiġi pprovduta aktar informazzjoni dwar is-sigurtà ta' din il-mediċina.
English: In the high baseline platelet count cohort, the mean baseline platelet count for the avatrombopag-treated patients was 44.3 x 109/L and for placebo-treated patients was 44.9 x 109/L.
Maltese: Fil-koort tal-għadd għoli tal-plejtlits fil-linja bażi, l-għadd medju tal-plejtlits fil-linja bażi għall-pazjenti ttrattati b'avatrombopag kien 44.3 x 109/L u għall-pazjenti ttrattati bi plaċebo kien 44.9 x 109/L.
English: Doptelet contains lactose
Maltese: Doptelet fih il-lactose
English: • low red blood cell count (anaemia)
Maltese: • għadd baxx ta' ċelluli tad-demm ħomor (anemija)
English: The gastric carcinoids were considered likely due to prolonged hypergastrinemia observed in toxicity studies.
Maltese: Il-karċinojdi gastriċi kienu meqjusa li x'aktarx seħħew minħabba ipergastrinemija fit-tul osservata fi studji dwar it-tossiċità.
English: Geometric mean ratio [90% CI] of avatrombopag PK with/without co administered drug (No Effect = 1.00)
Maltese: avatrombopag PK bi/mingħajr mediċina mogħtija fl-istess ħin (L-Ebda Effett = 1.00)
English: Animal studies are insufficient with respect to reproductive toxicity (see section 5.3).
Maltese: Studji f'annimali mhux biżżejjed biex juru xi effetti tossiċi fuq is-sistema riproduttiva (ara sezzjoni 5.3). L-użu ta'
English: In the high baseline platelet count cohort, the mean baseline platelet count for the avatrombopag-treated patients was 44.3 x 109/L and for placebo-treated patients was 44.5 x 109/L.
Maltese: Fil-koort tal-għadd għoli tal-plejtlits fil-linja bażi, l-għadd medju tal-plejtlits fil-linja bażi għall-pazjenti ttrattati b'avatrombopag kien 44.3 x 109/L u għall-pazjenti ttrattati bi plaċebo kien 44.5 x 109/L.
English: Do not give Doptelet to people less than 18 years old.
Maltese: Tagħtix Doptelet lil persuni li għandhom inqas minn 18-il sena.
English: 10 film-coated tablets 15 film-coated tablets
Maltese: 10 pilloli miksija b'rita 15-il pillola miksija b'rita
English: Doptelet 20 mg film-coated tablets
Maltese: Doptelet 20 mg pilloli miksija b'rita
English: The full EPAR for Memantine Accord can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Memantine Accord is available as tablets (5 mg, 10 mg, 15 mg and 20 mg) and can only be obtained with a prescription.
Maltese: Memantine Accord jiġi bħala pilloli (5 mg, 10 mg, 15 mg u 20 mg) u jista' jinkiseb biss b'riċetta ta' tabib.
English: Memantine Accord is a ‘generic medicine'.
Maltese: Memantine Accord huwa ‘mediċina ġenerika'.
English: This summary was last updated in 12-2013.
Maltese: Diċembru 2013.
English: Memantine Accord memantine
Maltese: Informazzjoni oħra dwar Memantine Accord
English: This is a summary of the European public assessment report (EPAR) for Memantine Accord.
Maltese: Dan huwa sommarju tar-Rapport Pubbliku Ewropew ta' Valutazzjoni (EPAR) għal Memantine Accord.
English: The active substance in Memantine Accord, memantine, is an antidementia medicine.
Maltese: Is-sustanza attiva f'Memantine Accord, il-memantina, hija mediċina kontra d-dimenzja.
English: Memantine works by blocking types of receptors called N-methyl-D-aspartate (NMDA) receptors, to which the neurotransmitter glutamate normally attaches.
Maltese: Memantina taħdem billi timblokka tipi ta' riċetturi msejħa riċetturi ta' N-methyl-D-aspartate (NMDA), li s-soltu jeħel magħhom in-newrotrażmettitur glutamat.
English: Memantine Accord is a medicine that contains the active substance memantine.
Maltese: Memantine Accord huwa mediċina li fiha s-sustanza attiva memantine.
English: A risk management plan has been developed to ensure that Memantine Accord is used as safely as possible.
Maltese: Pjan ta' ġestjoni tar-riskju ġie żviluppat biex jassigura li Memantine Accord jintuża bl-aktar mod sigur possibbli.
English: This means that Memantine Accord is similar to a ‘reference medicine' already authorised in the European Union (EU) called Axura.
Maltese: Dan ifisser li Memantine Accord huwa simili għall‘mediċina ta' referenza' diġà awtorizzata fl-Unjoni Ewropea (UE) li jisimha Axura.
English: Why is Memantine Accord approved?
Maltese: Għal xiex ġie approvat Memantine Accord?
English: It is used to treat patients with moderate to severe Alzheimer's disease, a type of dementia (a brain disorder) that gradually affects memory, intellectual ability and behaviour.
Maltese: Jintuża għall-kura ta' pazjenti b'marda ta' Alzheimer moderata sa gravi, li hija tip ta' dimenzja (disturb fil-moħħ) li bil-mod il-mod taffettwa l-memorja, il-kapaċità intellettwali u l-imġiba.
English: Neurotransmitters are chemicals in the nervous system that allow nerve cells to communicate with one another.
Maltese: In-newrotrażmettituri huma sustanzi kimiċi fissistema nervuża li jippermettu liċ-ċelluli tan-nervituri jikkomunikaw ma' xulxin.
English: Because Memantine Accord is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Maltese: Minħabba li Memantine Accord huwa mediċina ġenerika u huwa bijoekwivalenti għall-mediċina ta' referenza, il-benefiċċji u r-riskji tiegħu jitqiesu l-istess bħal dawk tal-mediċina ta' referenza.
English: EPAR summary for the public
Maltese: Sommarju tal-EPAR għall-pubbliku memantine
English: ‘Bioequivalent' means that the medicines are expected to produce the same levels of the active substance in the body.
Maltese: ‘Bijoekwivalenti' tfisser li l-mediċini huma mistennija li jipproduċu l-istess livelli tas-sustanza attiva filġisem.
English: The Committee recommended that Memantine Accord be approved for use in the EU.
Maltese: Il-Kumitat irrakkomanda li Memantine Accord ikun approvat għall-użu fl-UE.
English: The dose may need to be reduced in patients who have moderate or severe problems with their kidneys.
Maltese: Jista' jkun meħtieġ li titnaqqas id-doża f'pazjenti li jkollhom problemi moderati jew gravi filkliewi.
English: To prevent side effects, the dose of Memantine Accord is gradually increased over the first three weeks of treatment: during the first week, the daily dose is 5 mg; in the second week, it is 10 mg; and during the third week, it is 15 mg. From week four onwards, the recommended maintenance dose is 20 mg once a day.
Maltese: Sabiex jiġu evitati l-effetti sekondarji, id-doża ta' Memantine Accord tiżdied bil-mod il-mod matul l-ewwel tliet ġimgħat tal-kura: matul lewwel ġimgħa, id-doża tkun ta' 5 mg; fit-tieni ġimgħa din tkun ta' 10 mg; u matul it-tielet ġimgħa, id
English: No additional studies in patients were required as Memantine Accord was shown to have comparable quality and is considered to be bioequivalent to the reference medicine, Axura.
Maltese: Ma kien jinħtieġ l-ebda studju addizzjonali fil-pazjenti peress li Memantine Accord intwera li għandu kwalità komparabbli u huwa meqjus bħala bijoekwivalenti għall-mediċina ta' referenza, Axura.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Memantine Accord has been shown to have comparable quality and is considered bioequivalent to Axura.
Maltese: Il-Kumitat għall-Prodotti Mediċinali għall-Użu mill-Bniedem (CHMP) ikkonkluda li, b'mod konformi marrekwiżiti tal-UE, Memantine Accord wera li għandu kwalità komparabbli ma' u huwa meqjus bijoekwivlenti għal Axura.
English: The company provided data on the medicine's solubility, composition and absorption in the body.
Maltese: Il-kumpanija pprovdiet dejta dwar is-solubilità, il-kompożizzjoni u l-assorbiment tal-mediċina fil-ġisem.
English: Further information on Alpivab can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Alpivab is given as an infusion lasting 15 to 30 minutes.
Maltese: Alpivab jingħata bħala infużjoni li ddum bejn 15 sa 30 minuta.
English: Alpivab (peramivir) EMA/120516/2018
Maltese: EMA/120516/2018
English: Alpivab is an antiviral medicine that contains the active substance peramivir.
Maltese: Aplivab huwa mediċina antivirali li fiha s-sustanza attiva peramivir.
English: Other information about Alpivab
Maltese: Informazzjoni oħra dwar Alpivab
English: Serious side effects with Alpivab are anaphylaxis (a severe allergic reaction) and skin reactions, including erythema multiforme (an allergic skin reaction) and Stevens-Johnson Syndrome (life-threatening reaction with flu-like symptoms and painful rash affecting the skin, mouth, eyes and genitals).
Maltese: Effetti sekondarji serji b'Alpivab huma anafilassi (reazzjoni allerġika severa) u reazzjonijiet fil-ġilda, inklużi eritema multiformi (reazzjoni allerġika fil-ġilda) u s-sindrome ta' Stevens-Johnson (reazzjoni ta' periklu għall-ħajja b'sintomi simili għal dawk tal-influwenza u raxx li jikkawża uġigħ li jaffettwa l-ġilda, il-ħalq, l-għajnejn u l-ġenitali).
English: What are the risks associated with Alpivab?
Maltese: X'inhuma r-riskji assoċjati ma' Alpivab?
English: Alpivab was compared with placebo (a dummy treatment) in one main study of 296 adults with influenza (mostly influenza A) treated within 48 hours of symptoms appearing.
Maltese: Aplivab tqabbel ma' plaċebo (kura finta) fi studju ewlieni ta' 296 adult bl-influwenza (l-aktar linfluwenza A) li ġew ikkurati fi żmien 48 siegħa minn meta bdew jidhru s-sintomi.
English: The active substance in Alpivab, peramivir, prevents the flu virus from spreading further by blocking the activity of enzymes (proteins) on the surface of the virus called neuraminidases.
Maltese: Is-sustanza attiva f'Alpivab, peramivir, tipprevjeni lill-virus tal-influwenza milli jinfirex aktar billi timblokka l-attività tal-enzimi (proteini) fuq il-wiċċ tal-virus imsejjaħ newroaminidażi.
English: The dose depends on age and body weight and should be reduced in adults and adolescents over 13 years of age with reduced kidney function.
Maltese: Id-doża tiddependi mill-età u mill-piż tal-ġisem u għandha titnaqqas fl-adulti u fl-adoloxxenti li għandhom aktar minn 13-il sena b'funzjoni mnaqqsa tal-kliewi.
English: As for all medicines, data on the use of Alpivab are continuously monitored.
Maltese: Bħal fil-każ tal-mediċini kollha, id-data dwar l-użu ta' Alpivab hija ssorveljata kontinwament.
English: Alpivab is available as a solution to be diluted for infusion (drip) into a vein.
Maltese: Alpivab jiġi bħala soluzzjoni li għandha tiġi dilwita għall-infużjoni (dripp) fil-vina.
English: The most common side effects with Alpivab (which may affect up to around 3 in 100 people) are a decrease in the levels of neutrophils (a type of white blood cell) and nausea (feeling sick).
Maltese: L-effetti sekondarji l-aktar komuni b'Alpivab (li jistgħu jaffettwaw sa madwar 3 persuni minn kull 100) huma tnaqqis fil-livelli ta' newtrofili (tip ta' ċellola bajda tad-demm) u dardir (tħossok ma tiflaħx).
English: Peramivir works on neuraminidases of both influenza-A (the most common type) and influenza-B viruses.
Maltese: Peramivir taħdem fuq in-newramidażi kemm tal-virus tal-influwenza-A (it-tip l-aktar komuni) kif ukoll il-virus talinfluwenza-B.
English: For the full list of side effects and restrictions with Alpivab, see the package leaflet.
Maltese: Għal-lista sħiħa tal-effetti sekondarji u restrizzjonijiet b'Alpivab, ara l-fuljett ta' tagħrif.
English: How is Alpivab used?
Maltese: Kif jaħdem Alpivab?
English: Uncomplicated means that the flu has typical features (such as fever, aches, cough, sore throat and runny nose) and is not made worse by other conditions.
Maltese: Mhux ikkumplikata tfisser li l-influwenza għandha karatteristiċi tipiċi (bħal deni, uġigħ, sogħla, uġigħ fil-griżmejn u mnieħer iqattar) u ma tiggravax b'kundizzjonijiet oħrajn.
English: The main measure of effectiveness was the length of time before symptoms (cough, sore throat, headache, blocked nose, feverishness or chills, aches or pains of the muscle or joints and tiredness) got better.
Maltese: Il-kejl ewlieni taleffikaċja kien it-tul ta' żmien qabel ma s-sintomi (sogħla, uġigħ fil-griżmejn, uġigħ ta' ras, imnieħer miżdud, deni jew tertir, uġigħ fil-muskoli jew fil-ġogi u għejja) qalbu għall-aħjar.
English: Symptoms took around 2 and a half days (59 hours) to get better in patients taking Alpivab in comparison with just under 3 and a half days (82 hours) in patients taking placebo.
Maltese: madwar jumejn u nofs (59 siegħa) biex qalbu għall-aħjar f'pazjenti li kienu qed jieħdu Alpivab meta mqabbla ma' ftit inqas minn tlett ijiem u nofs (82 siegħa) f'pazjenti li kienu qed jieħdu l-plaċebo.
English: What measures are being taken to ensure the safe and effective use of Alpivab?
Maltese: X'miżuri qegħdin jittieħdu biex jiġi żgurat l-użu sigur u effettiv ta' Alpivab?
English: Side effects reported with Alpivab are carefully evaluated and any necessary action taken to protect patients.
Maltese: L-effetti sekondarji rrappurtati b'Alpivab huma evalwati bir-reqqa u kull azzjoni meħtieġa hi meħuda biex tipproteġi lill-pazjenti.
English: Alpivab was shown to reduce the length of time symptoms lasted in patients with influenza.
Maltese: Din il-mediċina tintuża biex tikkura influwenza mhux ikkumplikata (flu) fl-adulti u fi tfal li għandhom aktar minn sentejn.
English: The European Medicines Agency decided that Alpivab's benefits are greater than its risks and it can be authorised for use in the EU.
Maltese: L-Aġenzija Ewropea għall-Mediċini ddeċidiet li l-benefiċċji ta' Alpivab huma akbar mir-riskji tiegħu u li jista' jiġi awtorizzat għall-użu fl-UE.
English: The mutual recognition procedure (UK/V/0356/001/MR) started on 26 November 2009.
Maltese: Il-proċedura ta' rikonoxximent reċiproku (UK/V/0356/001/MR) inbdiet fis-26 ta' Novembru 2009.
English: The marketing authorisation holder, Norbrook Laboratories Ltd, submitted an application for Combisyn via a mutual recognition procedure in Austria, Belgium, Denmark, Finland, France, Portugal and Spain on the basis of the marketing authorisation granted by the United Kingdom.
Maltese: Id-detentur tal-awtorizzazzjoni għat-tqegħid fis-suq, Norbrook laboratories Ltd, issottometta applikazzjoni għal Combisyn permezz ta' proċedura ta' rikonoxximent reċiproku fl-Awstrija, fil-Belġju, fid-Danimarka, fil-Finlandja, fi Franza, fil-Portugall u fi Spanja abbażi tal-awtorizzazzjoni għat-tqegħid fis-suq mogħtija mir-Renju Unit.
English: Combisyn Lactating Cow Intramammary Suspension (Combisyn) is an intramammary suspension containing amoxicillin, clavulanic acid and prednisolone.
Maltese: Combisyn Sospensjoni Intramammarja għal Baqar li Jreddgħu (Combisyn) hija sospensjoni intramammarja li fiha amoxicillin, clavulanic acid u prednisolone.
English: Based on the evaluation of the rapporteur's assessment of the currently available data, the CVMP considered that the benefit/risk profile of Combisyn Lactating Cow Intramammary Suspension is negative, and therefore adopted an opinion on 6 April 2011 recommending the refusal of the granting of the marketing authorisations and suspension of the existing marketing authorisation.
Maltese: Abbażi tal-evalwazzjoni tal-valutazzjoni tar-relatur tad-dejta disponibbli attwalment, is-CVMP ikkunsidra li l-profil tal-benefiċċju/riskju ta' Combisyn Sospensjoni Intramammarja għal Baqar li Jreddgħu huwa negattiv, u għaldaqstant adotta opinjoni fis-6 ta' April 2011 li tirrakkomanda r-rifjut tal-għoti tal-awtorizzazzjoni għat-tqegħid fis-suq u s-sospensjoni tal-awtorizzazzjoni għat-tqedgħid fissuq eżistenti.
English: On 2 July 2010, the United Kingdom, as Reference Member State, referred the matter to the European Medicines Agency under Article 33(4) of Directive 2001/82/EC, due to concerns raised by a Concerned Member States, France, that the safety and efficacy of the product had not been sufficiently demonstrated.
Maltese: Fit-2 ta' Lulju 2010, ir-Renju Unit, bħala l-Istat Membru ta' Referenza, irrefera l-kwistjoni lill-Aġenzija Ewropea għall-Mediċini skont l-Artikolu 33(4) tad-Direttiva 2001/82/KE, minħabba tħassib imqajjem minn Stat Membru Kkonċernat, Franza, li s-sigurtà u l-effikaċja tal-prodott ma ntwerewx b'mod suffiċjenti.
English: There are several metabolites identified.
Maltese: Hemm bosta metaboliti identifikati.
English: dermatitis, photosensitivity rare:
Maltese: dermatite, fotosensittività rari:
English: County Kerry Ireland
Maltese: Killorglin, County Kerry Irlanda
English: Paediatric data
Maltese: Data Pedjatrika
English: toxic epidermal necrolysis (Lyell's syndrome)
Maltese: nekroliżi tossika tal-ġilda (Lyell's syndrome)
English: Tacrolimus is not compatible with PVC (polyvinylchloride) plastics.
Maltese: Tacrolimus mhux kompatibbli mal-PVC (polyvinylchloride).
English: Modigraf 1 mg granules for oral suspension EU/1/09/523/002
Maltese: Modigraf 1 mg granijiet gћal suspensjoni orali EU/1/09/523/002
English: Astellas Pharma a/s Tlf: + 45 43 430355
Maltese: Danmark Astellas Pharma a/s Tlf: + 45 43 430355
English: hypertonia very rare:
Maltese: ipertonija rari ħafna:
English: (> 98.8%) to plasma proteins, mainly to serum albumin and α-1-acid glycoprotein.
Maltese: Fil-plażma, tacrolimus jaqbad sewwa (> 98.8%) mal-proteini tal-plażma, l-aktar mas-serum albumin u l-α-1-acid glycoprotein.
English: Sachets consisting of layers of polyethylene terephtalate (PET), aluminium (Al) and polyethylene (PE).
Maltese: In-natura tal-kontenitur u ta' dak li hemm ġo fih Qratas magћmulin minn saffi ta' polyethylene terephtalate (PET), aluminju (Al) u polyethylene (PE).
English: Modigraf contains lactose and sodium
Maltese: Modigraf fih lactose u sodium
English: However, cases of spontaneous abortion have been reported.
Maltese: Madankollu, każijiet ta 'abort spontanju ġew irrapportati.
English: Intestinal transplantation
Maltese: Trapjant Intestinali
English: It is an immunosuppressant.
Maltese: Huwa immunosuppressant.
English: Decreases in AUC (2 to 12%) and Cmax (15 to 38%), and an increase in tmax (38 to 80%) in whole blood were evident.
Maltese: Tnaqqis fl-AUC (2 sa 12%) u Cmax (15 sa 38%), u żieda f'tmax (38 sa 80%) fid-demm sћiћ kienu evidenti.
English: - The other ingredients are: lactose monohydrate, hypromellose (E464) and croscarmellose sodium (E468).
Maltese: Lactose monohydrate, hypromellose (E 464) u croscarmellose sodium (E 468)
English: Decreases in AUC (27%) and Cmax (50%), and an increase in tmax (173%) in whole blood were evident.
Maltese: Tnaqqis fl-AUC(27%) u Cmax (50%), u żieda f'tmax (173%) fid demm sћiћ kienu evidenti.
English: Hypersensitivity to other macrolides.
Maltese: Sensittività eċċessiva għal makrolidi oћra.
English: haemolytic uraemic syndrome, anuria very rare:
Maltese: sindrome uremika emolitika, anuria rari ħafna:
English: Endocrine disorders rare:
Maltese: Disturbi fis-sistema endokrinarja rari:
English: Modigraf contains the active substance tacrolimus.
Maltese: Modigraf fih is-sustanza attiva tacrolimus.
English: In adult liver, kidney and heart transplant patients, values of 4.1 l/h, 6.7 l/h and 3.9 l/h, respectively, have been observed.
Maltese: Fi trapjanti tal-fwied, tal-kliewi u tal-qalb f'pazjenti adulti ħarġu rispettivament il-valuri ta' 4.1 l/h, 6.7 l/h u 3.9 l/h.
English: dehydration, hypoglycaemia, hypoproteinaemia, hyperphosphataemia
Maltese: deidrazzjoni, ipogliċemija, ipoprotenemija, iperfosfatemija
English: Tacrolimus is widely metabolised in the liver, primarily by the cytochrome P450-3A4.
Maltese: Tacrolimus jigi metabolizzat malajr fil-fwied, primarjament biċ-cytochrome P450-3A4.
English: hypoacusis rare:
Maltese: ipoakusis rari:
English: Each sachet contains 94.7 mg lactose (as monohydrate).
Maltese: Kull qartas fih 94.7 mg lactose (bħala monohydrate).
English: Astellas Pharma B.V.Branch Belgique/Belgien Tél/Tel: + 32 (0)2 5580710
Maltese: Luxembourg/Luxemburg Astellas Pharma B.V.Branch Belgique/Belgien Tél/Tel: + 32 (0)2 5580710
English: Gastrointestinal disorders
Maltese: Disturbi gastro- intestinali
English: The 1-year survival rates were 73.1% in the tacrolimus versus 79.2% in the ciclosporin group.
Maltese: F'sena kien hemm 73.1% tal-pazjenti li għexu wara li ħadu tacrolimus kontra 79.2% fil-grupp li ħadu ciclosporin.
English: Each sachet contains 473 mg lactose (as monohydrate).
Maltese: Kull qartas fih 473 mg lactose (bħala monohydrate).
English: Astellas Pharma s.r.o., Tel: +421 2 4444 2157
Maltese: Slovenská republika Astellas Pharma s.r.o., Tel: +421 2 4444 2157
English: Astellas Pharma GmbH Tel: + 49 (0)89 454401
Maltese: Deutschland Astellas Pharma GmbH Tel: + 49 (0)89 454401
English: There is also evidence of gastrointestinal metabolism by CYP3A4 in the intestinal wall.
Maltese: Hemm ukoll evidenza ta' metaboliżmu gastrointestinali bil-CYP3A4 fil-ħajt intestinali.
English: In vitro the following substances have been shown to be potential inhibitors of tacrolimus metabolism: bromocriptine, cortisone, dapsone, ergotamine, gestodene, lidocaine, mephenytoin, miconazole, midazolam, nilvadipine, norethisterone, quinidine, tamoxifen, troleandomycin.
Maltese: Dawn is-sustanzi li se nsemmu wrew in vitro li huma inibituri potenzjali tal-metaboliżmu ta' tacrolimus: bromocriptine, cortisone, dapsone, ergotamine, gestodene, lidocaine, mephenytoin, miconazole, midazolam, nilvadipine, norethistterone, quinidine, tamoxifen, troleandomycin.
English: 50 sachets containing granules for oral suspension.
Maltese: GĦAMLA FARMAĊEWTIKA U KONTENUT 50 qratas fihom granijiet gћal suspensjoni orali.
English: In adult and paediatric liver transplant patients, it averaged 11.7 hours and 12.4 hours, respectively, compared with 15.6 hours in adult kidney transplant recipients.
Maltese: F'pazjenti adulti u pedjatriċi li jagћmlu trapjant tal-fwied, il-medja kienet ta' 11.7 u 12.4 siegћa, rispettivament, mqabbel ma' 15.6 siegћat f'riċevituri adulti ta' trapjant tal-kliewi.